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Summary The effect of adriamycin on human and mouse CFUGM was examined at concentrations and times
suggested by plasma clearance data derived from the results of a number of published studies. Our results
suggest that the high concentrations of drug present in the plasma for short periods of time following infusion
are only weakly cytotoxic towards the CFUGM when incubated for similar times. In contrast, there was a
considerably greater cytotoxic effect when the drug was examined at low concentrations for periods similar to
those described for the terminal phase of adriamycin clearance. The principal metabolite, adriamycinol, was
poorly cytotoxic.
Adriamycin has found widespread application in
the treatment of many malignant disorders
including solid tumours, leukaemias and
lymphomas. It has made a significant contribution
to the treatment of acute myeloid leukaemia, given
as a repeated intravenous dose of 30-90mgm 2
according to the schedule used. There is a
cumulative cardiotoxic effect in about one third of
patients at 550mgm2, increasing at higher doses
and undoubtedly, this has limited the usefulness of
the drug. To attempt to lessen or overcome this
problem, a number of related anthracycline
derivatives are now undergoing appraisal
(Arcamone et al., 1979). In addition, and because
the cardiotoxic effect may be related to the initial
plasma concentration of the drug, several centres
have used different dose regimens based on critical
pharmacokinetic analysis (Legha et al., 1982). The
relationship between the plasma concentration and
the cytotoxicity of the drug is important and the
present paper attempts to examine this problem by
studying the effect of adriamycin at plasma
concentrations on the bone marrow CFUGM
population.
Based on detailed pharmacokinetic data
(Ehninger et al., 1980; Robert et al., 1982 and
Greene et al., 1983), we have examined the effect of
relatively high concentrations during short-term
pulse experiments and low concentrations during
long-term incubations. In the latter experiments, it
was necessary to incorporate the drug into the
CFUGM assay system during the 7-day incubation
period.
Early studies (Takanashi & Bachur, 1976)
suggested that adriamycin was extensively
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metabolised to produce a wide range of
compounds. However, subsequent work has shown
that most of these apparent metabolites were
artefactually produced during the analytical
procedure. Recent studies (Peterson & Paul, 1982;
Greene et al., 1983; Robert et al., 1982) have
demonstrated that only one metabolite,
adriamycinol, was present in the plasma, although
the aglycone has also been detected (Ehninger et
al., 1980).
We have therefore examined the effect of
adriamycinol during the long-term experiments and
also the effect of adriamycin aglycone, although the
role of this compound as a metabolite is
questionable. Also as an important comparison, we
have examined these effects on the murine CFUGM
population.
Materials and methods
Bone marrow
Bone marrow was obtained from ribs resected from
haematologically normal patients undergoing
thoracic surgery. In all instances, CFUGM growth
was within normal limits. Bone marrow was
obtained from the rib by cutting 2cm sections
which were then gently compressed to force out the
marrow. The marrow was collected into culture
medium and the particles dispersed by passage
through a 19G hypodermic syringe needle. The
resulting suspension was allowed to stand for about
ten minutes before the fat layer was removed. On
the basis of the number of mature blood cells
present, the preparation was essentially free from
peripheral blood contamination.
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Human CFUGM assay
Bone marrow cells were cultured in duplicate in
35mm petri dishes at a concentration of
0.2 x 106ml- 1 in a 1 ml volume of a-medium
containing nucleosides and nucleotides (Gibco
Europe Ltd.), 15% v/v newborn calf serum (Gibco,
Special Bobby Calf Serum) and 0.3% agar. Colony
stimulating factor was provided as human placenta
conditioned medium (Burgess et al., 1977) at a
concentration of 10% v/v. Batches of conditioned
medium were always selected on the basis of
comparable activity to the previous batch.
Incubation of the cells was for 7 days at 37°C in a
fully humidified incubator. The agar was then
overlaid with phosphate buffered saline containing
dilute Giemsa and the cells allowed to stain for
-1 h. Colonies, defined as aggregates of over forty
cells, were counted using an Olympus stereoscopic
microscope at x 40 magnification.
Mouse CFUGM assay
Mice used in these experiments were randomly bred
TO strain mice of both sexes. Bone marrow was
obtained by gently flushing the lumen of the femurs
with culture medium. Cells were used without
further preparation after appropriate dilution. Cells
at a concentration of 0.2 x 1Q6Mml1 were cultured
in a-medium containing 5% v/v newborn calf
serum and 15% donor horse serum (Gibco). Mouse
heart conditioned medium was used as a source of
colony stimulating factor (Byrne et al., 1978).
Incubation with adriamycin and derivatives
Stock solutions were prepared immediately prior to
use. Solutions of adriamycin and adriamycinol were
prepared in water and adriamycin aglycone in
dimethyl sulphoxide. These solutions were diluted
for use with culture medium.
For the short-term pulse experiments, the bone
marrow cells were incubated in suspension culture
usually at a concentration of 106 ml1 with a range
of drug concentrations. After incubation, the
reaction was stopped by diluting the cells with
phosphate buffered saline and after washing the
cells the CFUGM recovery was determined.
In the long-term experiments, the drugs were
incorporated into the CFUGM assay system and
therefore incubated for the seven day period only.
The results in the case of adriamycin are based
on six experiments and three experiments with the
derivatives. A different marrow preparation was
used for each experiment. The data for the long-
term experiments is plotted semi-logarithmically
and the positions of the lines determined by
regression analysis.
Results
Short-term pulse experiments
Selection of drug concentrations to be used in these
experiments is difficult because of the very rapid
decline in plasma concentrations during the
clearance phase. The concentrations selected were
1jM and 2jM. At higher concentrations, it was
difficult to monitor the cytotoxic effect accurately,
mainly because of the difficulty in washing the cells
free from excess drug. Exposure to adriamycin for
I h at a concentration of 2jM resulted in a loss of
-70% of the initial CFUGM (Figure 1). At the
1 jiM level, a decrease of -40% of the CFUGM was
observed. This concentration for 15min, as shown
by the first of the clearance curves, results in a loss
of CFUGM of < 10%.
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Figure 1 The effect of pulses of adriamycin on the
growth of human bone marrow CFUGM at 2MM (0),
and 1MM (@) concentrations (Mean+s.e.).
Long-term experiments
Figure 2 shows the effect of adiiamycin,
adriamycinol and adriamycin aglycone on human
CFUGM. The mean normal CFUGM count per
0.2 x 106 mononuclear cells was 193 + 119, range
32-580 (n=54). A 50% kill of CFUGM was
observed at an adriamycin concentration of 23 nM.
Adriamycinol was considerably less toxic with a
50% kill concentration some three-fold higher at
80nM. The aglycone was inactive.
Figure 3 shows similar results for the mouse
CFUGM population. The mean normal CFUGM
count per 0.2 x 106 cells was 233 +67, range 131-
300, (n=49). A 50% kill of CFUGM was observed
at an adriamycin concentration of 37nM,
somewhat higher than for the human CFUGM.
Similarly, there was a greater insensitivity towards
adriamycinol. In this case, a better fit of the data
was observed when the results were plotted as a
biphasic response showing no effect atEFFECT OF ADRIAMYCIN ON CFUGM 353
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Figure 2 The effect of adriar
(0) and adriamycin aglycone
human bone marrow CFUGM
was for 7 days in the soft;
human placenta conditioned
stimulating factor.
50 1OC
Conc
Figure 3 The effect of adriam
(0), and adriamycin aglycone
mouse bone marrow CFUGM (1
was for 7 days in the soft a
mouse heart conditioned mediui
stimulating factor.
concentrations of adriamycinol below about 90nM.
At the highest concentration examined of 200nM,
there was only a 35% loss of CFUGM number.
Again, the aglycone was inactive.
As detected by the Giemsa staining of the agar
plates, there was no change in the ratios of the
types of colonies produced in the presence of
adriamycin.
Discussion
The use of adriamycin in the treatment of a
number of haematological conditions prompted our
use of the bone marrow CFUGM population to
examine its cytotoxic effect. Although it might seem
attractive to employ an assay using either a
malignant cell population or a continuous (nM) leukaemic cell line, the diversity of the properties of
mycin (0), adriamycinol such cells would make the results very difficult to
(A), on the growth of interpret. In contrast, we have found that the effect
(Mean+ s.e.). Incubation of adriamycin on the normal CFUGM population is
agar assay system with remarkably consistent.
as a source of colony The drug concentrations used in our experiments
are based on plasma clearances obtained from a
number of studies using mainly high performance
liquid chromatography. Such studies (Benjamin et
_ a al., 1977; Chan et al., 1978; Ehninger et al., 1980;
.z Robert et al., 1982 and Greene et al., 1983) indicate
a multi-nhase vrocess for adriamvcin clearance In
broad terms, following infusion, the plasma
concentration is high for a short period of time
(<12min), but then remains at a very low
concentration for a number of davs. For examnle.
in one study (Greene et al., 1983), following a
15 min infusion of 75 mgm-2, there was a rapid
decline in concentration from 5/uM to 0.1 1iM
within 1h, but subsequent clearance was roughly
log-linear and a concentration of lOnM was
detected after 4 days. Results from other studies
have been very similar and we feel confident in
using these results in comparison with the results of
our studies.
Because of the rapid changes in concentrations
which are occurring in the plasma, particularly
during the initial phase, the concentrations used in
our experiments can only be a rough approximation
to the in vivo conditions. The concentrations
employed in the short-term experiments are
nrohnhlv rathPr high in, 'flk , 150 200 noted would be overestimated. Thus a
(nM) concentration of 1 MiM for 1 h is about ten-fold
ycin (0), adriamycinol higher than that suggested by the clearance patterns (A), on the growth of at this time. The resulting loss of CFUGM was about Mean+ s.e.). Incubation 40%. The same concentration during a 15 minute
gar assay system with incubation which reflects the plasma concentration
m as a source of colony more closely, killed < 10% of the initial CFUGM. It
would seem, therefore, that the cytotoxic effect of
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adriamycin during these short time incubations is
small.
Similar considerations also apply to the low
concentration - long-term effect. As mentioned
earlier, during these experiments it was necessary to
incubate the drug during the course of the 7-day
CFUGM assay period. Several studies have suggested
that significant levels of adriamycin are present in
the plasma at times approaching this period,
(Rosso et al., 1972; Robert et al., 1983; Greene et
al., 1983). For example, in the latter study at three
days post-infusion, plasma levels of adriamycin had
fallen to 25nM and at this concentration 50% loss
of CFUGM was observed in our assay system.
Because of the roughly logarithmic decrease in the
plasma concentration, the effective concentration
prior to three days would be significantly higher. It
would seem, therefore, that the cytotoxic effect of
these low concentrations was considerably higher
than that observed during the short-term high
concentration exposures. These results are of
interest in the light of pharmacokinetic data
(Greene et al., 1983), suggesting that the terminal
phase of adriamycin clearance is responsible for
75% of the total drug exposure. Clearly, the
concentrations found in the plasma during this
phase are indeed cytotoxic and may well play the
major part in the action of the drug.
Pharmacokinetic measurements show that
adriamycinol is produced in quantatively significant
amounts during the latter stages of clearance with
concentrations approaching those of the parent
drug. In our system, adriamycinol was markedly
less cytotoxic than the parent drug with a 50% kill
concentration of about 80nM, which is some 4-fold
greater than for adriamycin. Similar results have
been obtained in short-term experiments using a
human ovarian cancer assay system (Ozols et al.,
1980).
Evidence suggests that adriamycin aglycone is
probably not a metabolite of adriamycin and is
certainly not produced at significant levels. In our
experiments, it was not cytotoxic against the human
or mouse colony forming system.
Undoubtedly, our results can only be taken as an
approximation to the effectiveness of the drug in
vivo. A better indication of its therapeutic effect
might be obtained from its relative action on the
pluripotent stem cell population (for which, of
course, there is no human assay) and the malignant
cell population, for which again in the case of many
of the haematological malignancies, we do not have
adequate assay systems. However, we feel that our
results show that very low concentrations of
adriamycin are cytotoxic, at least towards the
CFUGM population. It is likely that the effectiveness
of these concentrations is a function in part of the
high affinity which most cells have towards
adriamycin and there is no reason to suppose that
other progenitor cells do not have a similar affinity
for the drug.
It has been suggested on pharmacokinetic
(Greene et al., 1983) and clinical grounds (Creasy et
al., 1976; Legha et al., 1982) that the anti-tumour
effect of adriamycin is dependent on the total dose
and independent of the programme by which it is
given, whereas the adverse side-effect and in
particular, cardiotoxicity, is a feature of the peak
drug concentrations. Our results prompt us to
suggest that the adverse side-effects of these peak
drug concentrations might be avoided if adriamycin
was used at much lower dosage.
This work was supported by the Leukaemia Research
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